Taken together, we aimed to evaluate, in silico and in vitro, the ability of minor phytocannabinoids to interact with and modulate important targets in developing ER+ breast cancer, namely aromatase, ERα, and AR, to expand our knowledge on these compounds and substantiate the development of new therapeutic solutions. This evidence concerns the gene ESR1 and breast carcinoma.